Loading viewer...
earnings
Format: PDF earnings
Five Prime Therapeutics presented its third quarter 2016 earnings update, highlighting progress in its oncology-focused pipeline with multiple clinical candidates including Cabiralizumab (FPA008), FPA144, and FP-1039. The company provided forward-looking guidance on clinical trial timelines, cash position, and operational metrics for full-year 2016.
earnings
28 Pages
Unknown
Ford Motor Company Q2 2016 Earnings Review
earningsearnings
50 Pages
Ford Motor Company